Save on Caplacizumab-YHDP with Coupons, Discounts & Savings Programs

Caplacizumab-YHDP is available as an 11 mg single-dose vial.

Caplacizumab-YHDP is an anti-von Willebrand Factor that is used to treat:
Acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressants (medications that lower your immune system)

Caplacizumab-YHDP treats aTTP by sticking to von Willebrand factor (vWF) in your blood. This prevents your platelets from clumping together to form clots and also keeps your platelet level in the rest of your body from dropping too low.

You typically start treatment of Caplacizumab-YHDP when you start your plasma exchange. Your first dose of Caplacizumab-YHDP is injected into the veins by a healthcare provider. After this, your doses of Caplacizumab-YHDP can be injected under the skin by a provider, yourself, or your caregiver.

1st day of treatment: The typical dose is 11 mg of Caplacizumab-YHDP injected into the veins (IV) at least 15 minutes before plasma exchange by a healthcare provider. Another 11 mg of Caplacizumab-YHDP is injected under the skin after your plasma exchange.

Treatment during daily plasma exchange: The typical dose is 11 mg of Caplacizumab-YHDP injected under the skin daily after plasma exchange.

Treatment after the last day of plasma exchange: The typical dose is 11 mg injected under the skin daily for about 1 month. Your provider might have you continue taking Caplacizumab-YHDP for up to about another month, depending on how you’re responding to the medication.

Caplacizumab-YHDP is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

• Common side effects of Caplacizumab-YHDP:
• Nosebleeds
• Headache
• Bleeding gums
• Feeling tired
• Rash and hives
• Fever
• "Pins and needles" feeling
• Difficulty breathing
• Back pain
• Muscle pain
• Urinary tract infection
• Bleeding at injection or catheter site

Serious side effects are rare with Caplacizumab-YHDP. Contact your healthcare provider immediately if you experience any of the following.

Severe bleeding: fast heart rate, dizziness, light-headedness, pale skin, blood in urine or stool, vomiting or couging up blood

• Concomitant use of anticoagulants or antiplatelet agents with Caplacizumab-YHDP may increase
• the risk of bleeding. Monitor closely for bleeding with concomitant use.

Various FDA-approved generic manufacturers

Caplacizumab-YHDP may increase the risk of bleeding in the fetus and neonate. Monitor neonates for
bleeding.
All patients receiving Caplacizumab-YHDP, including pregnant women, are at risk for bleeding.
Pregnant women receiving Caplacizumab-YHDP should be carefully monitored for evidence of
excessive bleeding.

• Cablivi